Zoetis Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zoetis Inc (ZTS)
Assess today's live Zoetis Inc (ZTS) share price, performance and insights using our live NYSE: ZTS stock exchange data.
Analyse the historical data and Zoetis Inc share price performance charts on this page. Our technical summary section provides analysis on Zoetis Inc share price buy/sell indicators using real-time data (or discuss the Zoetis Inc (ZTS) stock price today with other investors in the Zoetis Inc NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE ZTS share price (ISIN: US98978V1035) to enhance your trading decisions with our free investment tools and resources.
What Is the Zoetis Inc Share Price Today?
The Zoetis Inc share price today is 126.65.
What Is the Stock Symbol for Zoetis Inc
The stock symbol (or 'ticker') for Zoetis Inc is "ZTS."
What Stock Exchange Does Zoetis Inc Trade On?
Zoetis Inc is listed and trades on the NYSE stock exchange.
Is Zoetis Inc a Good Stock to Buy?
Determining whether Zoetis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Zoetis Inc share price performance charts on this page. Our technical summary section provides analysis on Zoetis Inc share price buy/sell indicators using real-time data (or discuss the Zoetis Inc (ZTS) stock price today with other investors in the Zoetis Inc NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE ZTS share price (ISIN: US98978V1035) to enhance your trading decisions with our free investment tools and resources.
What Is the Zoetis Inc Share Price Today?
The Zoetis Inc share price today is 126.65.
What Is the Stock Symbol for Zoetis Inc
The stock symbol (or 'ticker') for Zoetis Inc is "ZTS."
What Stock Exchange Does Zoetis Inc Trade On?
Zoetis Inc is listed and trades on the NYSE stock exchange.
Is Zoetis Inc a Good Stock to Buy?
Determining whether Zoetis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
125.65
130.65
52 wk Range
115.25
177.00
ZTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
125.65130.65
52 wk Range
115.25177.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZTS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
151.44
Upside
+19.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 13 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Zoetis Inc Company Profile
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Zoetis Inc SWOT Analysis
Market Leadership | Zoetis maintains dominance in animal health, with a robust portfolio spanning companion animal and livestock sectors, despite increasing competition |
Financial Resilience | Analysts project continued growth, with Q3 2024 organic revenue expected to rise 9.2%. Price targets range from $225 to $242, reflecting positive outlook |
Product Innovation | Explore Zoetis's key growth drivers, including Librela for canine osteoarthritis and Apoquel for dermatology, alongside a promising pipeline in oncology and cardiology |
Future Prospects | Delve into Zoetis's strategies for tapping untapped markets in animal anti-depressants and pain management, while navigating challenges like foreign exchange impacts |
Zoetis Inc Earnings Call Summary for Q4/2025
- Zoetis reported Q4 2025 EPS of $1.48 (5.71% above forecast) and revenue of $2.4 billion (1.69% above expectations), while returning $3.2 billion to shareholders in 2025.
- Despite strong earnings, Zoetis shares fell 1.96% in pre-market trading to $126.15, following a 6% drop in the previous session amid market volatility.
- Full-year 2025 revenue reached $9.5 billion (+2% YoY) with adjusted net income of $2.8 billion (+6% YoY), driven by strong performance in Simparica franchise and diagnostics.
- CEO Kristin Peck highlighted 'meaningful progress across portfolio and pipeline' as the company projects 3-5% organic revenue growth and 3-6% adjusted net income growth for 2026.
- Zoetis plans to launch Lenivia in EU and Canada in H1 2026, with FDA approval anticipated in 2027, while addressing competitive pressures in parasiticide and dermatology markets.
Last Updated: 12/02/2026, 15:04
Read Full TranscriptCompare ZTS to Peers and Sector
Metrics to compare | ZTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZTSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.0x | 19.3x | −0.5x | |
PEG Ratio | 1.99 | 0.05 | 0.00 | |
Price/Book | 16.0x | 2.3x | 2.6x | |
Price / LTM Sales | 5.6x | 2.6x | 3.3x | |
Upside (Analyst Target) | 14.5% | 18.8% | 47.0% | |
Fair Value Upside | Unlock | 13.1% | 5.7% | Unlock |
Analyst Ratings
11 Buy
9 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 151.44
(+19.57% Upside)
Earnings
Latest Release
Feb 12, 2026
EPS / Forecast
1.48 / 1.40
Revenue / Forecast
2.40B / 2.36B
People Also Watch
FAQ
What Is the Zoetis Inc (ZTS) Share Price Today?
The live Zoetis Inc share price today is 126.65
What Stock Exchange Does Zoetis Inc (ZTS) Trade On?
Zoetis Inc is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Zoetis Inc?
The stock symbol (also called a 'ticker') for Zoetis Inc is "ZTS."
Does Zoetis Inc Pay Dividends? What’s The Current ZTS Dividend Yield?
Yes, ZTS Pays Dividends to its Shareholders. The current Zoetis Inc dividend yield is 1.67%.
What Is the Current Zoetis Inc Market Cap?
As of today, Zoetis Inc market capitalisation is 53.46B.
What Is Zoetis Inc's (ZTS) Earnings Per Share (TTM)?
The Zoetis Inc EPS is currently 6.02 (Trailing Twelve Months).
When Is the Next Zoetis Inc Earnings Date?
Zoetis Inc's next earnings report will be released on 30/04/2026.
Is ZTS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Zoetis Inc moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Zoetis Inc Stock Split?
Zoetis Inc has split 0 times. (See the ZTS stock split history page for full effective split date and price information.)
How Many Employees Does Zoetis Inc Have?
Zoetis Inc has 14500 employees.
What is the current trading status of Zoetis Inc (ZTS)?
As of 17/02/2026, Zoetis Inc (ZTS) is trading at a price of 126.65, with a previous close of 126.65. The stock has fluctuated within a day range of 125.65 to 130.65, while its 52-week range spans from 115.25 to 177.00.
What Is Zoetis Inc (ZTS) Price Target According to Analysts?
The average 12-month price target for Zoetis Inc is USD151.44, with a high estimate of USD197 and a low estimate of USD130. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +19.57% Upside potential.
What Is the ZTS After Hours Price?
ZTS's last after hours stock price is 128.30, the stock has decreased by 1.65, or 1.30%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.